Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
Animals
Antineoplastic Agents, Immunological
/ pharmacology
Carcinoma, Hepatocellular
/ drug therapy
Disease Models, Animal
Drug Development
Drug Discovery
Epigenesis, Genetic
/ drug effects
Histone Deacetylase Inhibitors
/ pharmacology
Humans
Liver Neoplasms
/ drug therapy
Molecular Targeted Therapy
/ methods
Protein Kinase Inhibitors
/ pharmacology
Signal Transduction
/ drug effects
Treatment Outcome
Biomarker
Checkpoint inhibitors
Clinical trial
Fibrosis
Immunotherapy
Liver cancer
Mouse model
Next-generation sequencing
Non-alcoholic steatohepatitis
Targeted therapy
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Jul 2019
07 Jul 2019
Historique:
received:
06
04
2019
revised:
02
05
2019
accepted:
18
05
2019
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
7
1
2020
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) remains a global medical burden with rising incidence due to chronic viral hepatitis and non-alcoholic fatty liver diseases. Treatment of advanced disease stages is still unsatisfying. Besides first and second generation tyrosine kinase inhibitors, immune checkpoint inhibitors have become central for the treatment of HCC. New modalities like epigenetic therapy using histone deacetylase inhibitors (HDACi) and cell therapy approaches with chimeric antigen receptor T cells (CAR-T cells) are currently under investigation in clinical trials. Development of such novel drugs is closely linked to the availability and improvement of novel preclinical and animal models and the identification of predictive biomarkers. The current status of treatment options for advanced HCC, emerging novel therapeutic approaches and different preclinical models for HCC drug discovery and development are reviewed here.
Identifiants
pubmed: 31333307
doi: 10.3748/wjg.v25.i25.3136
pmc: PMC6626722
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Histone Deacetylase Inhibitors
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3136-3150Déclaration de conflit d'intérêts
Conflict-of-interest statement: Stintzing S received honoraria for talks and/or for advisory function from: Amgen, Bayer, Merck KGaA, Lilly, Sanofi, Roche, Takeda, Taiho, SIRTEX and Samsung. Ocker M is employee and shareholder of Bayer AG.
Références
Cancer Res. 2003 Oct 1;63(19):6496-500
pubmed: 14559842
Hepatology. 2004 Sep;40(3):667-76
pubmed: 15349906
J Clin Invest. 2006 Jun;116(6):1582-95
pubmed: 16710476
Liver Int. 2006 Jun;26(5):604-12
pubmed: 16762006
J Hepatol. 2006 Sep;45(3):370-6
pubmed: 16780996
Hepatology. 2007 Jan;45(1):42-52
pubmed: 17187432
Int J Biochem Cell Biol. 2007;39(7-8):1367-74
pubmed: 17412634
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Cancer Res. 2008 Aug 15;68(16):6779-88
pubmed: 18701503
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Cancer Res. 2009 Sep 15;69(18):7385-92
pubmed: 19723656
Cancer Res. 2009 Oct 15;69(20):8067-75
pubmed: 19826049
Cell Oncol. 2010 Jan 1;32(4):285-300
pubmed: 20208142
World J Biol Chem. 2010 May 26;1(5):55-61
pubmed: 21540990
Virchows Arch. 2011 Aug;459(2):129-39
pubmed: 21713366
Gastroenterology. 2012 May;142(5):1229-1239.e3
pubmed: 22342966
J Cancer. 2012;3:158-65
pubmed: 22514558
J Clin Oncol. 2012 Sep 20;30(27):3361-7
pubmed: 22915658
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Transl Oncol. 2013 Apr;6(2):143-57
pubmed: 23544167
Compr Physiol. 2013 Apr;3(2):567-98
pubmed: 23720323
J Clin Oncol. 2013 Oct 1;31(28):3517-24
pubmed: 23980084
J Clin Oncol. 2013 Oct 1;31(28):3509-16
pubmed: 23980090
Gut Liver. 2013 Nov;7(6):696-703
pubmed: 24312711
Clin Cancer Res. 2014 Apr 15;20(8):2072-9
pubmed: 24589894
PLoS One. 2014 Mar 04;9(3):e90608
pubmed: 24594856
Radiology. 2014 Jul;272(1):284-93
pubmed: 24708192
Cancer Res. 2014 Aug 15;74(16):4515-25
pubmed: 24848510
Curr Protoc Pharmacol. 2014 Sep 02;66:14.30.1-10
pubmed: 25181010
Lab Invest. 2014 Nov;94(11):1273-82
pubmed: 25199052
Clin Cancer Res. 2014 Dec 15;20(24):6418-28
pubmed: 25320357
Gut. 2016 Jan;65(1):134-43
pubmed: 25524262
J Clin Oncol. 2015 Feb 20;33(6):559-66
pubmed: 25547503
Expert Opin Investig Drugs. 2015 Mar;24(3):309-27
pubmed: 25547844
Invest New Drugs. 2015 Jun;33(3):729-39
pubmed: 25861764
Drug Discov Today. 2015 Jul;20(7):848-55
pubmed: 25908576
World J Gastroenterol. 2015 May 14;21(18):5445-53
pubmed: 25987766
Gastroenterology. 2015 Oct;149(4):1042-52
pubmed: 26052074
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
Korean J Hepatobiliary Pancreat Surg. 2015 Feb;19(1):1-5
pubmed: 26155269
Exp Toxicol Pathol. 2015 Oct;67(10):491-8
pubmed: 26198575
Annu Rev Med. 2016;67:103-17
pubmed: 26473416
Prz Gastroenterol. 2015;10(3):142-7
pubmed: 26516379
Hepatology. 2016 Mar;63(3):880-97
pubmed: 26659654
World J Gastroenterol. 2016 Jan 7;22(1):275-83
pubmed: 26755876
Cancer Sci. 2016 May;107(5):609-18
pubmed: 26882440
Nat Biotechnol. 2016 Apr;34(4):419-23
pubmed: 26928769
World J Gastroenterol. 2016 Feb 28;22(8):2494-502
pubmed: 26937137
J Hepatol. 2016 Aug;65(2):280-8
pubmed: 26952006
Oncotarget. 2016 Apr 12;7(15):20312-23
pubmed: 26967385
Oncotarget. 2016 May 17;7(20):28998-9010
pubmed: 27058414
Cancer Immunol Immunother. 2016 Jun;65(6):631-49
pubmed: 27138532
Oncotarget. 2016 Jun 7;7(23):34703-51
pubmed: 27167195
Hepatology. 2016 Dec;64(6):2038-2046
pubmed: 27359084
Oncotarget. 2016 Oct 25;7(43):69916-69926
pubmed: 27655712
J Gastroenterol. 2017 Apr;52(4):512-519
pubmed: 27704266
Anticancer Res. 2016 Nov;36(11):6179-6183
pubmed: 27793949
J Hepatol. 2017 Mar;66(3):545-551
pubmed: 27816492
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Methods Mol Biol. 2017;1559:279-296
pubmed: 28063051
Mol Oncol. 2017 Mar;11(3):320-334
pubmed: 28164434
J Biol Chem. 2017 Jun 16;292(24):10068-10086
pubmed: 28432125
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Biomark Cancer. 2017 Feb 28;9:1-9
pubmed: 28469485
Hepatology. 2017 Nov;66(5):1502-1518
pubmed: 28498607
Transl Oncol. 2017 Aug;10(4):511-517
pubmed: 28558264
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Drug Discov Today Technol. 2017 Mar;23:27-36
pubmed: 28647083
J Hepatol. 2017 Nov;67(5):999-1008
pubmed: 28687477
J Cancer. 2017 Jul 5;8(11):1988-1994
pubmed: 28819398
Mol Cancer. 2017 Aug 30;16(1):149
pubmed: 28854942
Hepatology. 2018 Mar;67(3):1132-1149
pubmed: 28862760
Gastroenterol Hepatol (N Y). 2017 Jul;13(7):398-410
pubmed: 28867968
Sci Rep. 2017 Sep 5;7(1):10499
pubmed: 28874716
Gastroenterology. 2018 Jan;154(1):195-210
pubmed: 28918914
Cancer Control. 2017 Jul-Sep;24(3):1073274817729243
pubmed: 28975834
Clin Cancer Res. 2018 Mar 15;24(6):1248-1259
pubmed: 28982688
J Hepatol. 2018 Feb;68(2):230-237
pubmed: 29128391
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):41-51
pubmed: 29275361
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
PLoS One. 2018 Mar 15;13(3):e0193802
pubmed: 29543828
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Front Med (Lausanne). 2018 Mar 26;5:78
pubmed: 29632864
World J Gastroenterol. 2018 May 14;24(18):1989-1994
pubmed: 29760542
Curr Opin Pharmacol. 2018 Aug;41:74-78
pubmed: 29772420
Cancer Biomark. 2018;22(3):511-521
pubmed: 29843214
J Exp Clin Cancer Res. 2018 May 29;37(1):110
pubmed: 29843754
Biomed Res Int. 2018 Apr 23;2018:9472939
pubmed: 29850590
Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309
pubmed: 29861325
Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):536-554
pubmed: 29904153
J Mol Diagn. 2018 Sep;20(5):686-702
pubmed: 29936259
Adv Exp Med Biol. 2018;1061:139-147
pubmed: 29956212
World J Gastroenterol. 2018 Jun 28;24(24):2605-2616
pubmed: 29962817
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Sci Rep. 2018 Jul 6;8(1):10283
pubmed: 29980757
Gene. 2018 Nov 15;676:47-55
pubmed: 29981417
Neoplasia. 2018 Aug;20(8):800-812
pubmed: 29981501
Mol Cancer Res. 2018 Nov;16(11):1713-1723
pubmed: 30082483
Gut. 2019 Jun;68(6):1065-1075
pubmed: 30108162
World J Gastroenterol. 2018 Sep 7;24(33):3695-3708
pubmed: 30197476
Invest New Drugs. 2018 Dec;36(6):1072-1084
pubmed: 30198057
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
World J Gastroenterol. 2018 Sep 21;24(35):3974-3979
pubmed: 30254402
Hepatol Res. 2019 Jan;49(1):14-32
pubmed: 30308081
World J Gastroenterol. 2018 Oct 28;24(40):4536-4547
pubmed: 30386103
Hepatol Int. 2019 Jan;13(1):51-57
pubmed: 30515676
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
J Cancer Res Ther. 2018 Dec;14(Supplement):S1188-S1192
pubmed: 30539869
Cancer Immunol Immunother. 2019 Mar;68(3):379-393
pubmed: 30547218
Front Immunol. 2018 Dec 03;9:2740
pubmed: 30559740
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
ESMO Open. 2018 Dec 10;3(Suppl 1):e000455
pubmed: 30622744
Cell Immunol. 2019 Feb;336:66-74
pubmed: 30626493
Front Med. 2019 Feb;13(1):3-11
pubmed: 30659408
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Gastroenterology. 2019 May;156(6):1731-1741
pubmed: 30738047
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):247-256
pubmed: 30791763
Biosci Trends. 2019 Mar 14;13(1):10-22
pubmed: 30799321
Chem Biol Interact. 2019 Apr 25;303:70-78
pubmed: 30826251
Hepatology. 1997 Mar;25(3):619-23
pubmed: 9049208